Identification of high-risk subjects in nonalcoholic fatty liver disease
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Non-alcoholic fatty liver disease (NAFLD) is becoming the most common liver disease worldwide, and its burden is expected to increase due to the growing epidemic of obesity and diabetes. The key challenge among NAFLD patients is to identify those with advanced fibrosis (F3F4), who are at high risk of developing complications and will benefit from specialized management and treatment with new pharmacotherapies when they are approved. Liver biopsy appears unrealistic and unsuitable in practice, given the large number of high-risk patients and its well-known limitations. Non-invasive sequential algorithms using fibrosis-4 index as first-line test, followed by vibration-controlled transient elastography or patented blood test, are the best strategy for case finding of high-risk subjects. In fact, they are now recommended by several international guidelines, and should be used and disseminated to increase awareness among physicians beyond liver clinics where most NAFLD patients are seen.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is becoming the most common liver disease worldwide, and its burden is expected to increase due to the growing epidemic of obesity and diabetes. The key challenge among NAFLD patients is to identify those with advanced fibrosis (F3F4), who are at high risk of developing complications and will benefit from specialized management and treatment with new pharmacotherapies when they are approved. Liver biopsy appears unrealistic and unsuitable in practice, given the large number of high-risk patients and its well-known limitations. Non-invasive sequential algorithms using fibrosis-4 index as first-line test, followed by vibration-controlled transient elastography or patented blood test, are the best strategy for case finding of high-risk subjects. In fact, they are now recommended by several international guidelines, and should be used and disseminated to increase awareness among physicians beyond liver clinics where most NAFLD patients are seen.
참고문헌 (36)
- Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
- Powell EE, "Non-alcoholic fatty liver disease", Lancet, 397, pp.2212~2224 (2021)
- Singh S, "Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis : a systematic review and meta-analysis of paired-biopsy studies", Clin Gastroenterol Hepatol, 13, pp.643~654 (2015)
- Kanwal F, "Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease", Hepatology, 71, pp.808~819 (2020)
- Estes C, "Modeling NAFLD disease burden in China, noninvasive tests of liver fibrosis with resulting clinical implications", Clin Gastroenterol Hepatol (2022)[DOI]
- Patel P, "A pragmatic approach identifies a high rate of nonalcoholic fatty liver disease with advanced fibrosis in diabetes clinics and at-risk populations in primary care", Hepatol Commun, 2, pp.893~905 (2018)
- McPherson S, "Age as a confounding factor for the accurate noninvasive diagnosis of advanced NAFLD fibrosis", Am J Gastroenterol, 112, pp.740~751 (2017)
- Qadri S, "Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease", J Clin Endocrinol Metab, 107, pp.e2008~e2020 (2022)
- Unalp-Arida A, "Noninvasive fatty liver markers predict liver disease mortality in the U. S. population", Hepatology, 63, pp.1170~1183 (2016)
- Hagström H, "Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease", J Hepatol, 73, pp.1023~1029 (2020)
- Vali Y, "FibroTest for evaluating fibrosis in non-alcoholic fatty liver disease patients:A systematic review and meta-analysis", J Clin Med, 10, pp.2415~ (2021)
- Vali Y, "Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD:A systematic review and meta-analysis", J Hepatol, 73, pp.252~262 (2020)
- Van Dijk AM, "Systematic review with meta-analyses : Diagnostic accuracy of FibroMeter tests in patients with non-alcoholic fatty liver disease", J Clin Med, 10, pp.2910~ (2021)
- Guillaume M, "Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres", Aliment Pharmacol Ther, 50, pp.1214~1222 (2019)
- Boursier J, "New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD", J Hepatol, 71, pp.389~396 (2019)
- Castera L, "Noninvasive algorithms for the case finding of"At-Risk"patients with NAFLD", Semin Liver Dis, 42, pp.313~326 (2022)
- Friedrich-Rust M, "Critical comparison of elastography methods to assess chronic liver disease", Nat Rev Gastroenterol Hepatol, 13, pp.402~411 (2016)
- Eddowes PJ, "Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease", Gastroenterology, 156, pp.1717~1730 (2019)
- Siddiqui MS, "Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 17, pp.156~163 (2019)
- Selvaraj EA, "Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis", J Hepatol, 75, pp.770~785 (2021)
- Tsochatzis EA, "Non-alcoholic fatty liver disease and the interface between primary and secondary care", Lancet Gastroenterol Hepatol, 3, pp.509~517 (2018)
- Majumdar A, "Defining the minimum acceptable diagnostic accuracy of noninvasive fibrosis testing in cirrhosis : A decision analytic modeling study", Hepatology, 71, pp.627~642 (2020)
- Canivet CM, "Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD", Hepatology (2022)[DOI]
- Boursier J, "Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events", J Hepatol, 76, pp.1013~1020 (2022)
- Mansour D, "Embedding assessment of liver fibrosis into routine diabetic review in primary care", JHEP Rep, 3, pp.100293~ (2021)
- Glyn-Owen K, "The combined effect of alcohol and body mass index on risk of chronic liver disease : A systematic review and meta-analysis of cohort studies", Liver Int, 41, pp.1216~1226 (2021)
- Harman DJ, "Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice : A cross-sectional study using transient elastography", Aliment Pharmacol Ther, 47, pp.504~515 (2018)
- Innes H, "Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity", Hepatology, 75, pp.369~378 (2022)
- Newsome PN, "FibroScan-AST(FAST)score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis : a prospective derivation and global validation study", Lancet Gastroenterol Hepatol, 5, pp.362~373 (2020)
- Noureddin M, "MRI-based(MAST)score accurately identifies patients with NASH and significant fibrosis", J Hepatol, 76, pp.781~787 (2022)
- Jung J, "MRE combined with FIB-4(MEFIB)index in detection of candidates for pharmacological treatment of NASH-related fibrosis", Gut, 70, pp.1946~1953 (2021)
- Kim BK, "Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD", J Hepatol, 77, pp.1482~1490 (2022)
- Noureddin M, "MEFIB vs MAST and FAST : Not a competition but useful tools", J Hepatol (2022)[DOI]
- Castera L, "Prospective head-to-head comparison of FAST, MAST, MEFIB, NFS and FIB-4 scores for diagnosing fibrotic NASH in patients with type 2 diabetes", Hepatology, 76(Suppl), pp.S86~ (2022)
- Younossi ZM, "A global survey of physicians knowledge about nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 20, pp.e1456~e1468 (2022)
- Lazarus JV, "Advancing the global public health agenda for NAFLD: A consensus statement", Nat Rev Gastroenterol Hepatol, 19, pp.60~78 (2022)